Two Large Hospitals Won't Give New Alzheimer's Drug

A pair of large hospitals are declining to administer Biogen Inc.’s BIIB -6.74% new Alzheimer’s treatment Aduhelm, the latest rupture to emerge from the Food and Drug Administration’s controversial approval of the drug last month. The Cleveland Clinic and Mount Sinai Health

Medicare to Review Coverage for New Alzheimer's Drug Aduhelm

Medicare officials are beginning a review of Biogen Inc.’s new Alzheimer’s drug to decide whether to standardize coverage of the medicine nationally, a widely-anticipated step that would allow the government to place limits on who can receive the medicine. The review of

FDA Narrows Suggested Uses for New Alzheimer's Drug

U.S. health regulators narrowed the prescribing instructions for the first new Alzheimer’s drug in nearly two decades, recommending the therapy be given to people with early-stage symptoms of the disease. The change recommends use of the drug, Aduhelm from Biogen Inc., be

Eli Lilly to Seek FDA Approval for Alzheimer's Drug

Eli Lilly & Co. plans to seek approval for its Alzheimer’s drug later this year, a sign that regulators are accelerating the prospects of treatments for the disease after a recent approval. Lilly said Thursday that the U.S. Food and Drug Administration

FDA Approved Alzheimer's Drug Despite Some Staff Concerns

The U.S. Food and Drug Administration approved the first new Alzheimer’s drug in decades over the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos. In the internal memos released Tuesday, FDA